Cobalt complexes as modulators against amyloid-β aggregation.

Area of Science:

• Biochemistry
• Neuroscience
• Materials Science

Background:

• Amyloid-β (Aβ) peptide aggregation is a hallmark of Alzheimer's disease, leading to cognitive decline.
• Transition metal complexes offer potential for modulating Aβ aggregation but face challenges with toxicity.
• Controlling Aβ assembly and toxicity is crucial for developing Alzheimer's disease therapeutics.

Purpose of the Study:

• To investigate cobalt-macrocycle complexes as modulators of Aβ peptide aggregation and toxicity.
• To explore the structure-activity relationship of cobalt complexes with Cyclam and DMC ligands in Aβ modulation.
• To assess the efficacy and safety of selected cobalt complexes in mitigating Aβ-induced cellular damage.

Main Methods:

• Synthesis and characterization of cobalt complexes with Cyclam and DMC ligands.
• Mechanistic studies on the interaction between cobalt complexes and Aβ peptides.
• Evaluation of Aβ aggregation pathways using the prepared cobalt complexes.
• Assessment of cellular toxicity of both Aβ peptides and cobalt complexes.

Main Results:

• Cobalt complexes, specifically [Co(Cyclam)(NO3)](NO3), [Co(Cyclam)(Cl)2]Cl, [Co(DMC)(H2O)2](NO3)2, and [Co(DMC)(Cl)2]Cl, were synthesized and characterized.
• These complexes form adducts with Aβ peptides, redirecting aggregation from fibril formation to amorphous clusters and shorter fibrils.
• The cobalt complexes effectively mitigated Aβ-induced toxicity in living cells with minimal intrinsic toxicity.

Conclusions:

• Cobalt-macrocycle complexes serve as effective chemical modulators for controlling Aβ amyloidogenesis.
• The study provides a framework for designing metal complexes with tailored properties to combat Aβ-related pathologies.
• These findings highlight a promising therapeutic strategy for Alzheimer's disease by targeting Aβ aggregation pathways.